ΠΜΣ Εργαστηριακή και Κλινική Νοσηλευτική ΚαρδιολογίαLibrary of the School of Health Sciences
Σπυρίδων Δευτεραίος, Αναπληρωτής Καθηγητής, Ιατρική, ΕΚΠΑ
Αχιλλέας Ζαχαρούλης, Καρδιολόγος Επιμελητής Α΄ΕΣΥ, Β΄Πανεπιστημιακή Καρδιολογική Κλινική, Π.Γ.Ν."ΑΤΤΙΚΟΝ"
Γεώργιος Γιαννόπουλος, Καρδιολόγος Επιμελητής Β΄Καρδιολογική Κλινική, Γ.Ν.Α. "Γ. Γεννηματάς"
Συγκριτική μελέτη της σχετιζόμενης με την υγεία ποιότητας ζωής σε ασθενείς με κολπική μαρμαρυγή που λαμβάνουν κουμαρινικά αντιπηκτικά έναντι νεωτέρων από του στόματος αντιπηκτικών
Comparative study of health-related quality of life in patients with atrial fibrillation receiving coumarin anticoagulants versus new oral anticoagulants
Introduction: Atrial fibrillation (AF) is the most common arrhythmia in daily clinical
practice and is associated with a 5-fold increase in stroke risk (Stroke Stroke).
Anticoagulation is necessary to reduce the risk for stroke. Vitamin K antagonists have been
the only drugs available in this category over the past decades. Novel Oral Anticoagulants
(NOACs) present a fixed dose response and do not require regular International Normalized
Ratio (INR) measurement.
Purpose: To assess the health-related quality of life of Greek patients with AF under
anticoagulant treatment and to show differences in the type of treatment.
Methodology: The population of the survey consists of 100 patients, ≥ 18 years who
hospitalized at the cardiology clinic or patients visiting the cardiology clinic of the Athens
General Hospital «G. Gennimatas», between January and December 2017. The study
population consists of two groups: group A includes patients receiving coumarin
anticoagulants and group B, patients receiving a newer oral anticoagulant. The assessment of
the health-related quality of life (HRQL) of AF patients based on the ShortForm-36 (SF-36)
Results: EHRA scores showed a difference between the two groups of patients and in
particular a high proportion (35.4%) of patients receiving coumarin anticoagulants had no
symptoms compared to the lowest percentage of patients receiving NOACs (21.2%) (p =
0.036). The analysis of the dimensions of quality of life based on SF-36 did not show a
statistically significant difference between the two groups, demonstrating that the quality of
life of patients with AF was not affected by taking coumarin anticoagulants or NOACs.
However, the mean in the bodily pain dimension for patients receiving coumarin
anticoagulants was lower compared to patients receiving NOACs.
Conclusions: It is estimated that the results of the survey will help health professionals
dealing with patients with AF to better understand their physical and mental health and their
treatment-related needs with immediate improvement. Taking the patient's preference into
"joint decision-making" for choosing the type of anticoagulant could improve patients'
Key words: atrial fibrillation, quality of life, treatments
Main subject category:
Atrial fibrillation, Quality of life, Treatments
Number of references: